Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,379.34 116.78 0.72%
S&P 500 1,856.52 13.54 0.73%
NASDAQ 4,066.21 32.05 0.79%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes

  Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes

Business Wire

NEW YORK -- October 24, 2013

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to
sell $1.5 billion of senior unsecured notes: $500,000,000 million in aggregate
principal amount of 1.750% notes due 2019, $500,000,000 million in aggregate
principal amount of 3.250% notes due 2023 and $500,000,000 million in
aggregate principal amount of 4.500% notes due 2044, in an underwritten public

Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital
Inc., BNP Paribas Securities Corp., Credit Suisse Securities (USA) LLC and RBS
Securities Inc. are acting as joint book-running managers of the underwriters.

Bristol-Myers Squibb intends to use the net proceeds from the offering for
general corporate purposes, including the repayment of all or a portion of its
commercial paper borrowings. The offering is expected to close on October 31,
2013, subject to customary closing conditions.

When available, the final prospectus supplement and accompanying prospectus
relating to the offering of the notes may be obtained by contacting one of the
following joint book-running managers:

  * Deutsche Bank Securities Inc., at: 800-503-4611
  * J.P. Morgan Securities LLC, at: 212-834-4533
  * Barclays Capital Inc., at: 888-603-5847
  * BNP Paribas Securities Corp., at: 800-854-5674
  * Credit Suisse Securities (USA) LLC, at: 800-221-1037
  * RBS Securities Inc., at: 866-884-2071

The final prospectus supplement and accompanying prospectus, when available,
may also be accessed through the SEC’s website at

These securities are offered pursuant to a registration statement that has
become effective under the Securities Act of 1933, as amended. These
securities are only offered by means of the prospectus supplement and
prospectus relating to the offering. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there be
any offer or sale of these securities in any state or other jurisdiction,
where the offer, solicitation or sale of these securities would be unlawful
prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert
or change any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can be
guaranteed. Forward-looking statements in this press release should be
evaluated together with the many risks and uncertainties that affect
Bristol-Myers Squibb's business, including those identified in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31, 2012,
particularly under "Item 1A. Risk Factors". Bristol- Myers Squibb undertakes
no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases.


Bristol-Myers Squibb Company
Laura Hortas, 609-252-4587
Ranya Dajani, 609-252-5330
Ryan Asay, 609-252-5020
Sponsored Links
Sponsored Links